Denali Therapeutics Inc

NAS:DNLI (USA)  
$ 20.50 -0.25 (-1.2%) 11:08 PM EST
At Loss
P/B:
2.75
Volume:
782.90K
Avg Vol (2M):
1.32M
Also Trade In:
Volume:
782.90K
At Loss
Avg Vol (2M):
1.32M

Business Description

Description
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Name Current Vs Industry Vs History
Cash-To-Debt 19.8
Equity-to-Asset 0.89
Debt-to-Equity 0.05
Debt-to-EBITDA -0.29
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 13.65
Distress
Grey
Safe
Beneish M-Score -0.04
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
3-Year Revenue Growth Rate -6.9
3-Year Book Growth Rate -7.9
Name Current Vs Industry Vs History
5-Day RSI 53.59
9-Day RSI 53.19
14-Day RSI 53.72
6-1 Month Momentum % -3.58
12-1 Month Momentum % -11.44

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 13.65
Quick Ratio 13.65
Cash Ratio 13.27
Days Sales Outstanding 7.01

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4.7
Shareholder Yield % 0.24

Financials (Next Earnings Date:2024-05-08 Est.)

DNLI's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:DNLI

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Denali Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 330.531
EPS (TTM) ($) -1.08
Beta 0.7
Volatility % 52.83
14-Day RSI 53.72
14-Day ATR ($) 1.073337
20-Day SMA ($) 20.5385
12-1 Month Momentum % -11.44
52-Week Range ($) 15.45 - 33.31
Shares Outstanding (Mil) 139.16

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Denali Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Denali Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Denali Therapeutics Inc Frequently Asked Questions

What is Denali Therapeutics Inc(DNLI)'s stock price today?
The current price of DNLI is $20.50. The 52 week high of DNLI is $33.31 and 52 week low is $15.45.
When is next earnings date of Denali Therapeutics Inc(DNLI)?
The next earnings date of Denali Therapeutics Inc(DNLI) is 2024-05-08 Est..
Does Denali Therapeutics Inc(DNLI) pay dividends? If so, how much?
Denali Therapeutics Inc(DNLI) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1